• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott's FreeStyle Libre® 3 Plus Sensor in the United States

    6/20/25 8:30:00 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care
    Get the next $TNDM alert in real time by email

    Tandem continues to build its technology ecosystem to expand choice and personalization for people living with diabetes

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor. The Company has initiated an early access program in the United States (U.S.), and intends to scale availability in the second half of 2025.

    "Diabetes management is not one-size-fits-all and it is critical for people living with diabetes to be able to personalize their AID systems to fit their unique healthcare and lifestyle needs," said Dr. Jordan Pinsker, chief medical officer of Tandem Diabetes Care. "The American Diabetes Association recommends AID systems as the preferred insulin delivery method in people with type 1 and other types of insulin-deficient diabetes, and this integration with Abbott's latest generation sensor allows even more CGM users to access the life-changing benefits of our Control-IQ+ technology."

    The FreeStyle Libre 3 Plus sensor has an extended 15-day wear time, transmitting automatic glucose readings every minute directly to the pump. This data is also available to view on the Tandem t:slim mobile app, providing users with multiple, convenient ways to access their current glucose trend.

    The t:slim X2 insulin pump is powered by Control-IQ+ technology, the latest generation of Tandem's advanced hybrid closed-loop algorithm, which adjusts insulin every 5 minutes based on predicted glucose values. It's the only system with the unique AutoBolus™ feature that calculates and delivers a correction bolus to help with missed meal boluses.* Control-IQ+ is easy to start, use, and personalize, and this latest integration works with the FreeStyle Libre 3 Plus sensor and extends its benefits to even more people with diabetes.

    "This is an exciting first step in our strategy to connect Tandem's portfolio of insulin pumps to Abbott's FreeStyle Libre 3 Plus sensors worldwide," said John Sheridan, president and chief executive officer of Tandem Diabetes Care. "We look forward to expanding access to our t:slim X2 users outside of the U.S. beginning later this year."

    When available, Tandem will email eligible users in the U.S. with more information.†

    About Tandem Diabetes Care

    Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company's pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit tandemdiabetes.com.

    Follow Tandem Diabetes Care on X @tandemdiabetes; use #tslimX2 #TandemMobi and #TandemDiabetes.

    Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.

    Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

    Forward Looking Statements

    This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, our ability to provide the software update for current t:slim X2 pump users and the t:slim X2 pumps pre-loaded with Freestyle Libre 3 Plus sensor integration software. These statements are subject to numerous risks and uncertainties, including our ability to sustain commercial scale manufacturing of the t:slim X2 pumps pre-loaded with Freestyle Libre 3 Plus sensor integration software, our ability to operate and maintain a system to facilitate online training for existing t:slim X2 pump customers upgrading their existing devices, and the risk that we may encounter other challenges that may delay the availability of the software update for current t:slim X2 pump users or the t:slim X2 pumps pre-loaded with Freestyle Libre 3 Plus sensor integration software. These and other risks are identified and described in greater detail under the "Risk Factors" heading of our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events, or other factors.

    Important Safety Information – FreeStyle Libre Systems

    Product for prescription only; for Important Safety Information, please visit FreeStyleLibre.us.

    Important Safety Information – Tandem Diabetes Care

    RX ONLY. The t:slim X2 pump with interoperable technology (the pump) and Control-IQ+ technology (Control-IQ+) are intended for single patient use. The pump and Control-IQ+ are indicated for use with NovoLog or Humalog U-100 insulin. t:slim X2 insulin pump: The pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater. Control-IQ+ technology: Control-IQ+ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ+ technology is intended for the management of Type 1 diabetes mellitus in persons 2 years of age and greater and of Type 2 diabetes mellitus in persons 18 years of age and greater.

    WARNING: Control-IQ+ should not be used in anyone under the age of 2 years old with Type 1 diabetes or under the age of 18 years old with Type 2 diabetes. It should also not be used in patients who require less than a total daily insulin dose of 5 units of insulin per day or who weigh less than 20 pounds (9 kilograms), as those are the required minimum values needed for Control-IQ+ to operate safely.

    Users of the pump and Control-IQ+ must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use. Failure to follow these instructions for use could result in an over delivery or under delivery of insulin. This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Visit tandemdiabetes.com/safetyinfo for additional important safety information.

    © 2025 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ+, t:slim X2, t:slim, and Tandem Mobi are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. All other third-party marks are the property of their respective owners.

    * If glucose values are predicted to be above 180 mg/dL (or 10.0 mmol/L), Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 110 mg/dL (or 6.1 mmol/L) and delivers 60% of that value.

    † Future updates for all or some Tandem products may not be developed and may not be offered everywhere and would be subject to applicable regulatory approvals. Software updates are only available to customers who are in warranty at the time they update their pump. Additional training may be required to access certain software updates. Charges may apply. Tandem may discontinue select software and features over time at its discretion.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250620369593/en/

    Media Contact:

    858-366-6900

    [email protected]

    Investor Contact:

    858-366-6900

    [email protected]

    Get the next $TNDM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TNDM

    DatePrice TargetRatingAnalyst
    6/16/2025$24.00Hold
    Truist
    4/10/2025$20.00Neutral
    Mizuho
    3/5/2025$45.00 → $22.00Overweight → Equal-Weight
    Morgan Stanley
    3/4/2025$35.00 → $24.00Buy → Neutral
    Citigroup
    3/3/2025$38.00 → $22.00Overweight → Equal Weight
    Wells Fargo
    2/28/2025$35.00 → $25.00Outperform → Mkt Perform
    Bernstein
    12/2/2024$45.00Equal-Weight → Overweight
    Morgan Stanley
    11/6/2024$42.00Outperform
    Bernstein
    More analyst ratings

    $TNDM
    SEC Filings

    See more
    • SEC Form SD filed by Tandem Diabetes Care Inc.

      SD - TANDEM DIABETES CARE INC (0001438133) (Filer)

      5/29/25 4:42:26 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders

      8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)

      5/23/25 4:21:45 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Inc. filed SEC Form 8-K: Other Events

      8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)

      5/12/25 5:16:49 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2025 results after the financial markets close on Wednesday, August 6, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI0d

      7/1/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott's FreeStyle Libre® 3 Plus Sensor in the United States

      Tandem continues to build its technology ecosystem to expand choice and personalization for people living with diabetes Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor. The Company has initiated an early access program in the United States (U.S.), and intends to scale availability in the second half of 2025. "Diabetes management is not one-size-fits-all and it is critical for people living with diabetes to be able to personalize their

      6/20/25 8:30:00 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes. The Abbott sensor, currently under development, will combine glucose and ketone sensing technology that aims to help people living with diabetes detect early ketone rise to avoid life-threatening diabetic ketoacidosis. "Integrating our advanced insulin delivery systems with Abbott's future glucose-ketone sensor has the potential to help

      6/10/25 8:30:00 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technology Officer Carpenter Rick converted options into 406 shares and covered exercise/tax liability with 207 shares, increasing direct ownership by 0.95% to 21,219 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      6/18/25 4:08:32 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • EVP & CHIEF COMMERCIAL OFFICER Novara Mark David converted options into 7,414 shares and covered exercise/tax liability with 3,846 shares, increasing direct ownership by 14% to 28,763 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      6/18/25 4:08:21 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Director Cha Myoungil converted options into 1,749 shares, increasing direct ownership by 15% to 13,699 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      6/18/25 4:08:10 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & Chief Operating Officer Kyrillos Jean-Claude bought $190,966 worth of shares (10,538 units at $18.12) (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      3/11/25 6:06:01 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • EVP & CHIEF COMMERCIAL OFFICER Novara Mark David bought $12,364 worth of shares (532 units at $23.24) (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      11/19/24 5:23:14 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Allen Dick bought $94,778 worth of shares (5,000 units at $18.96), increasing direct ownership by 33% to 19,962 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      11/29/23 4:10:39 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • February 28, 2025 - FDA Roundup: February 28, 2025

      For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

      2/28/25 5:00:47 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • November 7, 2023 - FDA Roundup: November 7, 2023

      For Immediate Release: November 07, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA issued a Safety Communication warning consumers, health care providers, and health care facilities not to use recalled saline (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC. On November 6, Nurse

      11/7/23 3:38:18 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Tandem Diabetes Care with a new price target

      Truist initiated coverage of Tandem Diabetes Care with a rating of Hold and set a new price target of $24.00

      6/16/25 7:53:54 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Mizuho initiated coverage on Tandem Diabetes Care with a new price target

      Mizuho initiated coverage of Tandem Diabetes Care with a rating of Neutral and set a new price target of $20.00

      4/10/25 12:43:51 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Tandem Diabetes Care from Overweight to Equal-Weight and set a new price target of $22.00 from $45.00 previously

      3/5/25 7:47:44 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Financials

    Live finance-specific insights

    See more
    • Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2025 results after the financial markets close on Wednesday, August 6, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI0d

      7/1/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Announces First Quarter 2025 Financial Results

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2025. First Quarter 2025 Highlights, Financial Results Compared to First Quarter 2024 Achieved record first quarter sales with worldwide growth of 22% Increased pump sales in the United States by 19% on a GAAP basis and 17% on a non-GAAP(1) basis, on strong shipment growth and average selling price improvement Delivered 5 point adjusted EBITDA(1) margin increase Approximately 30% of U.S. lives now covered through pharmacy benefits for Tandem Mobi Benefits of Control-IQ Technology were featured for a fourth time i

      4/30/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2025 results after the financial markets close on Wednesday, April 30, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI72222

      4/3/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Leadership Updates

    Live Leadership Updates

    See more
    • Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude "JC" Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620151195/en/Jean-Claude "JC" Kyrillos (Photo: Business Wire) "JC brings deep experience in healthcare and a great balance of technical, operational, and leadership skills from multipl

      6/20/24 9:00:00 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care, Inc investors: Please contact the Portnoy Law Firm to recover your losses; November 2, 2023 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio

      11/7/23 3:47:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care, Inc investors: Please contact the Portnoy Law Firm to recover your losses; November 2, 2023 deadline.

      Investors can contact the law firm at no cost to learn more about recovering their losses ​LOS ANGELES, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' opti

      11/1/23 8:03:30 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

      SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

      11/14/24 4:15:44 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

      SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

      9/9/24 10:40:31 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Tandem Diabetes Care Inc.

      SC 13G - TANDEM DIABETES CARE INC (0001438133) (Subject)

      2/14/24 7:37:31 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care